Evidence map›Paper›PMID 29992381›Full record

ArticleWorld journal of urology2019

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.

Matteo Ferro, Mihai Dorin Vartolomei, Giorgio Ivan Russo, Francesco Cantiello, Abdal Rahman Abu Farhan, Daniela Terracciano, Amelia Cimmino, Savino Di Stasi, Gennaro Musi, Rodolfo Hurle and 25 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer.International journal of molecular sciences · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 19 institutions in 6 countries.

Matteo FerroDivision of Urology, European Institute of Oncology, Milan, Italy. matteo.ferro@ieo.it.
Mihai Dorin VartolomeiDivision of Urology, European Institute of Oncology, Milan, Italy.
Giorgio Ivan RussoDepartment of Urology, University of Catania, Catania, Italy.
Francesco CantielloDepartment of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Abdal Rahman Abu FarhanDepartment of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Daniela TerraccianoDepartment of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.
Amelia CimminoInstitute of Genetics and Biophysics "A. Buzzati Traverso", National Research Council (CNR), Naples, Italy.
Savino Di StasiUrology Unit, Policlinico Tor Vergata, University of Rome, Rome, Italy.
Gennaro MusiDivision of Urology, European Institute of Oncology, Milan, Italy.
Rodolfo HurleDepartment of Urology, Istituto Clinico Humanitas, Clinical and Research Hospital, Milan, Italy.
Vincenzo SerrettaDivision of Urology, University of Palermo, Palermo, Italy.
Gian Maria BusettoDepartment of Urology, Sapienza University of Rome, Rome, Italy.
Ettore De BerardinisDepartment of Urology, Sapienza University of Rome, Rome, Italy.
Antonio CioffiDivision of Urology, European Institute of Oncology, Milan, Italy.
Sisto PerdonàUro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"-IRCCS, Naples, Italy.
Marco BorghesiDepartment of Urology, University of Bologna, Bologna, Italy.
Riccardo SchiavinaDepartment of Urology, University of Bologna, Bologna, Italy.
Gabriele CozziDivision of Urology, European Institute of Oncology, Milan, Italy.
Gilberto L AlmeidaDepartment of Urology, University of Vale do Itajaí, Itajaí, Brazil.
Pierluigi BoveDepartment of Experimental Medicine and Surgery, Urology Unit, Azienda Policlinico Tor Vergata, Rome, Italy.
Estevao LimaDepartment of CUF Urology and Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal.
Giovanni GrimaldiDepartment of CUF Urology and Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal.
Deliu Victor MateiDivision of Urology, European Institute of Oncology, Milan, Italy.
Nicolae CrisanDepartment of Urology, University of Medicine and Pharmacy, "Iuliu Hațieganu", Cluj-Napoca, Romania.
Matteo MutoDepartment of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Naples, Italy.
Paolo VerzeDepartment of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy.
Michele BattagliaDepartment of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.
Giorgio GuazzoniDepartment of Urology, Istituto Clinico Humanitas, Clinical and Research Hospital, Milan, Italy.
Riccardo AutorinoDivision of Urology, Virginia Commonwealth University, Richmond, VA, USA.
Giuseppe MorgiaDepartment of Urology, University of Catania, Catania, Italy.
Rocco DamianoDepartment of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Ottavio de CobelliDivision of Urology, European Institute of Oncology, Milan, Italy.
Shahrokh ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Vincenzo MironeDepartment of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy.
Giuseppe LucarelliDepartment of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0001-7807-1229
European Institute of Oncology · ITMagna Graecia University · ITUniversity of Naples Federico II · ITIuliu Hațieganu University of Medicine and Pharmacy · ROPoliclinico Tor Vergata · ITSapienza University of Rome · ITUniversity of Bari Aldo Moro · ITUniversity of Bologna · ITUniversity of Catania · ITUniversity of Minho · PTCornell University · USFederico II University Hospital · ITInstitute of Genetics and Biophysics · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITUniversidade do Vale do Itajaí · BRUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversity of Milan · ITUniversity of Palermo · ITVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC).

methodsA total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression.

resultsAfter re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.89%) were negative. During follow-up, 678 (64.82%) suffered recurrence, and 303 (30%) progression, 150 (14.34%) died of all causes, and 77 (7.36%) died of bladder cancer. At multivariate analysis, tumor size (hazard ratio [HR]:1.3; p = 0.001), and multifocality (HR:1.24; p = 0.004) were significantly associated with recurrence (c-index for the model:55.98). Overweight (HR: 4; p < 0.001) and obesity (HR:5.33 p < 0.001) were significantly associated with an increased risk of recurrence. Addition of the BMI to a model that included standard clinicopathological factors increased the C-index by 9.9. For progression, we found that tumor size (HR:1.63; p < 0.001), multifocality (HR:1.31; p = 0.01) and concomitant CIS (HR: 2.07; p < 0.001) were significant prognostic factors at multivariate analysis (C-index 63.8). Overweight (HR: 2.52; p < 0.001) and obesity (HR: 2.521 p < 0.001) were significantly associated with an increased risk of progression. Addition of the BMI to a model that included standard clinicopathological factors increased the C-index by 1.9.

conclusionsThe BMI could have a relevant role in the clinical management of T1G3 NMIBC, if associated with bladder cancer recurrence and progression. In particular, this anthropometric factor should be taken into account at initial diagnosis and in therapeutic strategy decision making.

Indexed as

CystectomyAdjuvants, ImmunologicAdministration, IntravesicalAgedAged, 80 and overBCG VaccineBody Mass IndexCarcinoma, Transitional CellChemotherapy, AdjuvantComorbidityCystoscopyDisease-Free SurvivalDisease ProgressionFemaleHumansMaleAdjuvants, ImmunologicBCG VaccineBladder cancerBody mass indexObesityPrognosis

Identifiers

PMID29992381
OpenAlexW2854223583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.